Citations

Clear

3942 citation(s) found for "To, Van".

Advanced Respiratory Support in the Contemporary Cardiac ICU
Metkus, Thomas S. , Miller, P. Elliott , Alviar, Carlos L. , Baird-Zars, Vivian M., Bohula, Erin A. , Cremer, Paul , Keeley, Ellen C. , Kontos, Michael C. , Menon, Venu , Park, Jeong‐Gun , Schulman, Steven P. , Katz, Jason N. , Bohula, Erin A , Cremer, Paul C , Gerber, Daniel , Jentzer, Jacob C. , Roswell, Robert O. , Solomon, Michael A. , Diepen, Sean van , Morrow, David A.

Mayo Clinic

Critical Care Explorations | September 18, 2020 | Volume: 2 | Issue: 9 | Pages: e0182

10.1097/cce.0000000000000182 | PMID 33235999 Get It

Objectives: The medical complexity and critical care needs of patients admitted to cardiac ICUs are increasing, and prospective studies examining the underlying cardiac and noncardiac diagnoses, the management strategies, and the prognosis of cardiac ICU patients with respiratory failure are needed. Design: Prospective cohort study. Setting: The Critical Care Cardiology Trials Network is a research collaborative of cardiac ICUs across the United States and Canada. Patients: We included all medical cardiac ICU admissions at 25 cardiac ICUs during two consecutive months annually at each center from 2017 to 2019. Measurements: We evaluated the use of advanced respiratory therapies including invasive mechanical ventilation, noninvasive ventilation, and high-flow nasal cannula versus no advanced respiratory support across admission diagnoses and the association with in-hospital mortality. Main Results: Of 8,240 cardiac ICU admissions, 1,935 (23.5%) were treated with invasive mechanical ventilation, 573 (7.0%) with noninvasive ventilation, and 281 (3.4%) with high-flow nasal cannula. Admitting diagnoses among those with advanced respiratory support were diverse including general medical problems in patients with heart disease as well as primary cardiac problems. In-hospital mortality was higher in patients who received invasive mechanical ventilation (38.1%; adjusted odds ratio, 2.53; 2.02–3.16) and noninvasive ventilation or high-flow nasal cannula (8.8%; adjusted odds ratio, 2.25; 1.73–2.93) compared with patients without advanced respiratory support (4.6%). Reintubation rate was 7.6%. The most common variables associated with respiratory insufficiency included heart failure, infection, chronic obstructive pulmonary disease, and pulmonary vascular disease. Conclusions: One-third of cardiac ICU admissions receive respiratory support with associated increased mortality. These data provide benchmarks for quality improvement ventures in the cardiac ICU, inform cardiac critical care training and staffing patterns, and serve as foundation for future studies aimed at improving outcomes.
Developments in evidence creation for treatments of inborn errors of metabolism
Stöckler‐Ipsiroglu, Sylvia , Yuskiv, Nataliya, Tingley, Kylie , Karnebeek, Clara D.M. van , Patterson, Marc, Potter, Beth K. , Patterson, Marc C.

Mayo Clinic

Journal of Inherited Metabolic Disease | September 18, 2020 | Volume: 44 | Issue: 1 | Pages: 88-98

10.1002/jimd.12315 | PMID 32944978 Get It

AbstractInborn errors of metabolism (IEM) represent the first group of genetic disorders, amenable to causal therapies. In addition to traditional medical diet and cofactor treatments, new treatment strategies such as enzyme replacement and small molecule therapies, solid organ transplantation, and cell‐and gene‐based therapies have become available. Inherent to the rare nature of the single conditions, generating high‐quality evidence for these treatments in clinical trials and under real‐world conditions has been challenging. Guidelines developed with standardized methodologies have contributed to improve the practice of care and long‐term clinical outcomes. Adaptive trial designs allow for changes in sample size, group allocation and trial duration as the trial proceeds. n‐of‐1 studies may be used in small sample sized when participants are clinically heterogeneous. Multicenter observational and registry‐based clinical trials are promoted via international research networks. Core outcome and standard data element sets will enhance comparative analysis of clinical trials and observational studies. Patient‐centered outcome‐research as well as patient‐led research initiatives will further accelerate the development of therapies for IEM.
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease
Fajgenbaum, David C. , Wu, David , Goodman, Aaron M. , Chadburn, Amy , Srkalović, Gordan , Leitch, Heather A. , Jayanthan, Raj , Schey, Steve , Oksenhendler, Éric , Lechowicz, Mary Jo , Hoffmann, Christian , Pemmaraju, Naveen , Bagg, Adam , Lim, Megan S. , group, the Castleman Disease Collaborative Network Scientific Advisory Board diagnostic criteria international working group and treatment guidelines international working, Wong, Raymond S M , Ferrero, Simone , Dispenzieri, Angela , Zinzani, Pier Luigi , van Rhee, Frits , Fajgenbaum, David C , Lim, Megan S , Wong, Raymond , Nasta, Sunita , Mukherjee, Sudipto , Ferrero, Simone , Sato, Yasuharu , Dispenzieri, Angela , Zinzani, Pier Luigi , Fosså, Alexander , Rhee, Frits van , group, the Castleman Disease Collaborative Network Scientific Advisory Board diagnostic criteria international working group and treatment guidelines international working

Mayo Clinic

American Journal of Hematology | September 16, 2020 | Volume: 95 | Issue: 12 | Pages: 1553-1561

10.1002/ajh.25992 | PMID 32894785 Get It

AbstractIdiopathic multicentric Castleman disease (iMCD) is a rare immunologic disorder characterized by systemic inflammation, multicentric lymphadenopathy, and organ dysfunction. Enlarged lymph nodes demonstrate a spectrum of characteristic but variable histopathologic features historically categorized into hyaline vascular (HV) (or hypervascular [HyperV] more recently), plasmacytic, or “mixed.” Though the etiology is unknown, a pro‐inflammatory cytokine storm, often involving interleukin‐6 (IL‐6), contributes to pathogenesis. Anti‐IL‐6 therapy with siltuximab is the only FDA‐ or EMA‐approved treatment based on efficacy and safety in multiple studies. Importantly, no patients considered to have HV histopathology achieved the primary endpoint in the Phase II study. NCCN currently recommends siltuximab first‐line for iMCD, except for patients considered to have HV histopathology. We investigated whether histopathologic subtype should guide siltuximab treatment decisions. Secondary analyses of clinical trial and real‐world data revealed similar clinical benefit across histopathologic subtypes. Notably, only 18 of 79 patients in the Phase II study were consistently classified into histopathologic subtype by three independent review panels, demonstrating limited reliability to guide treatment decisions. Real‐world data further demonstrate siltuximab's effectiveness in patients considered to have HV (or HyperV). Though histopathology is a critical component for diagnosis, there is insufficient evidence to guide treatment based solely on lymph node histopathologic subtype.
Age and Shock Severity Predict Mortality in Cardiac Intensive Care Unit Patients with and without Heart Failure
Padkins, Mitchell , Breen, Thomas , Anavekar, Nandan S., Henry, Timothy D. , Baran, David A. , Barsness, Gregory W. , Holmes, David R. , Jentzer, Jacob C. , Jentzer, Jacob C , Baran, David A , Padkins, Mitchell R , Diepen, Sean van , Kashani, Kianoush

Mayo Clinic

ESC Heart Failure | September 15, 2020 | Volume: 7 | Issue: 6 | Pages: 3971-3982

10.1002/ehf2.12995 | PMID 32909377 Get It

Abstract Aims Age is an important risk factor for mortality among patients with cardiogenic shock and heart failure (HF). We sought to assess the extent to which age modified the performance of the Society for Cardiovascular Angiography and Interventions (SCAI) shock stage for in-hospital and 1 year mortality in cardiac intensive care unit (CICU) patients with and without HF. Methods and results We retrospectively reviewed unique admissions to the Mayo Clinic CICU during 2007–2015 and stratified patients by age and SCAI shock stage. The association between age and in-hospital mortality was analysed using multivariable logistic regression, and 1 year mortality was analysed using Cox proportional hazards analysis, both in the entire cohort and among patients with an admission diagnosis of HF or acute coronary syndrome (ACS). The final study population included 10 004 unique patients with a mean age of 67 ± 15 years, including 46.1% with HF and 43.1% with ACS. Older patients more frequently had HF and had more extensive co-morbidities, higher illness severity, more organ failure, and differential use of critical care therapies. The percentage of patients with SCAI shock stages A, B, C, D, and E were 46%, 30%, 16%, 7%, and 1%, respectively. Patients with HF were older, had greater severity of illness and higher SCAI shock stage, and had higher rates of death at all time points. In-hospital mortality occurred in 908 (9%) patients, including 549 (12%) patients with HF (61% of all hospital deaths). Age was independently associated with hospital mortality (adjusted odds ratio per 10 years 1.3, 95% confidence interval 1.2–1.4, P < 0.001) and 1 year mortality (adjusted hazard ratio per 10 years 1.2, 95% confidence interval 1.2–1.3, P < 0.001) in the overall cohort. The associations of age with both hospital mortality (adjusted odds ratio 1.6 vs. 1.3 per 10 years older) and 1 year mortality (adjusted hazard ratio 1.5 vs. 1.3 per 10 years older) were higher for patients with ACS compared with patients with HF. Older age was associated with higher adjusted hospital mortality and 1 year mortality in each SCAI shock stage (all P < 0.05). Additive increases in both hospital mortality and 1 year mortality were observed with increasing age and SCAI shock stage. Conclusions Age is an independent risk factor for mortality that modifies the relationship between the SCAI shock stage and mortality risk in CICU patients, providing robust risk stratification for in-hospital and 1 year mortality. Although patients with HF had a higher risk of dying, age was more strongly associated with mortality among patients with ACS.
Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine
Gerotziafas, Grigoris , Catalano, Mariella, Pécsvárady, Zsolt, Wautrecht, Jean Claude, Olinic, Dan-Mircea , Farkas, Katalin , Elalamy, Ismaı̈l , Fareed, Jawed , Papageorgiou, Chryssa, Arellano, Rosella S., Agathagelou, Petros, Antic, Darco, Auad, Luciana, Banfić, Ljiljana , Bartolomew, John R., Benczúr, Béla , Bernardo, M., Boccardo, Francesco M., Cifkova, Renate, Marchi, Sergio De , Dimakakos, Evangelos , Dimitrov, Gabriel, Edmonds, Michael , Nazar, Essam Abo El, Erer, Dilek , Esponda, Omar L. , Gschwandtner, Michael E., Gu, Yongquan , Heinzmann, Mónica, Hamadé, A. , Jatoi, Noor-Ahmed, Karahan, Oğuz , Karplus, Thomas E., Klein‐Weigel, Peter, Kolossváry, Endre , Kozak, Matija, Lefkou, Eleftheria , Lessiani, Gianfranco , Marcoccia, Antonella , Marshang, Peter, Marakomichelakis, George , Matuška, Jiří , Moraglia, Luc, Pillon, Sergio , Poredoš, Pavel , Salvador, David Raymund K., Schlager, Oliver , Schernthaner, G. , Sieron, Alexander, Spaak, Jonas , Spyropoulos, Alex C. , Stanek, Agata , Štvrtinová, Viera, Tafur, Alfonso , Dreden, Patrick Van , Vardas, Panagiotis E., Vasić, Dragan , Wennberg, Paul W. , Zhai, Zhenguo , Committee, Scientific Reviewer, Catalano, M. , Gerotziafas, Grigoris T , Wennberg, Paul, Catalano, Mariella , Dimakakos, Evangelos , Farkas, Katalin , Stanek, Agata , Colgan, Mary Paula , Fazeli, Bahare , Falanga, Anna , Cosmi, Benilde , Dimopoulos, Meletios Α. , Durand‐Zaleski, Isabelle , Gresele, Paolo , Hamburg, Naomi M. , Karetová, Debora , Liew, Aaron , Marschang, Peter , Prior, Manlio , Sprynger, Muriel , Šuput, Dušan , Szuba, Andrzej , Vardas, Panagiotis E., Vikkula, Miikka , Committee, Scientific Reviewer

Mayo Clinic

Thrombosis and Haemostasis | September 13, 2020 | Volume: 120 | Issue: 12 | Pages: 1597-1628

10.1055/s-0040-1715798 | PMID 32920811 Get It

AbstractCOVID-19 is also manifested with hypercoagulability, pulmonary intravascular coagulation, microangiopathy, and venous thromboembolism (VTE) or arterial thrombosis. Predisposing risk factors to severe COVID-19 are male sex, underlying cardiovascular disease, or cardiovascular risk factors including noncontrolled diabetes mellitus or arterial hypertension, obesity, and advanced age. The VAS-European Independent Foundation in Angiology/Vascular Medicine draws attention to patients with vascular disease (VD) and presents an integral strategy for the management of patients with VD or cardiovascular risk factors (VD-CVR) and COVID-19. VAS recommends (1) a COVID-19-oriented primary health care network for patients with VD-CVR for identification of patients with VD-CVR in the community and patients' education for disease symptoms, use of eHealth technology, adherence to the antithrombotic and vascular regulating treatments, and (2) close medical follow-up for efficacious control of VD progression and prompt application of physical and social distancing measures in case of new epidemic waves. For patients with VD-CVR who receive home treatment for COVID-19, VAS recommends assessment for (1) disease worsening risk and prioritized hospitalization of those at high risk and (2) VTE risk assessment and thromboprophylaxis with rivaroxaban, betrixaban, or low-molecular-weight heparin (LMWH) for those at high risk. For hospitalized patients with VD-CVR and COVID-19, VAS recommends (1) routine thromboprophylaxis with weight-adjusted intermediate doses of LMWH (unless contraindication); (2) LMWH as the drug of choice over unfractionated heparin or direct oral anticoagulants for the treatment of VTE or hypercoagulability; (3) careful evaluation of the risk for disease worsening and prompt application of targeted antiviral or convalescence treatments; (4) monitoring of D-dimer for optimization of the antithrombotic treatment; and (5) evaluation of the risk of VTE before hospital discharge using the IMPROVE-D-dimer score and prolonged post-discharge thromboprophylaxis with rivaroxaban, betrixaban, or LMWH.
Structural Models for the Dynamic Effects of Loss-of-Function Variants in the Human SIM1 Protein Transcriptional Activation Domain
Coban, Matt , Blackburn, Patrick R. , Whitelaw, Murray L. , Haelst, Mieke M. van , Atwal, Paldeep S. , Caulfield, Thomas R. , Coban, Mathew A , Blackburn, Patrick , Atwal, Paldeep S , Caulfield, Thomas R

Mayo Clinic

Biomolecules | September 13, 2020 | Volume: 10 | Issue: 9 | Pages: 1314

10.3390/biom10091314 | PMID 32932609 Get It

Single-minded homologue 1 (SIM1) is a transcription factor with numerous different physiological and developmental functions. SIM1 is a member of the class I basic helix-loop-helix-PER-ARNT-SIM (bHLH–PAS) transcription factor family, that includes several other conserved proteins, including the hypoxia-inducible factors, aryl hydrocarbon receptor, neuronal PAS proteins, and the CLOCK circadian regulator. Recent studies of HIF-a-ARNT and CLOCK-BMAL1 protein complexes have revealed the organization of their bHLH, PASA, and PASB domains and provided insight into how these heterodimeric protein complexes form; however, experimental structures for SIM1 have been lacking. Here, we describe the first full-length atomic structural model for human SIM1 with its binding partner ARNT in a heterodimeric complex and analyze several pathogenic variants utilizing state-of-the-art simulations and algorithms. Using local and global positional deviation metrics, deductions to the structural basis for the individual mutants are addressed in terms of the deleterious structural reorganizations that could alter protein function. We propose new experiments to probe these hypotheses and examine an interesting SIM1 dynamic behavior. The conformational dynamics demonstrates conformational changes on local and global regions that represent a mechanism for dysfunction in variants presented. In addition, we used our ab initio hybrid model for further prediction of variant hotspots that can be engineered to test for counter variant (restoration of wild-type function) or basic research probe.
Global epigenetic alterations of mesenchymal stem cells in obesity: the role of vitamin C reprogramming
Afarideh, Mohsen , Thaler, Roman , Khani, Farzaneh , Jordan, Kyra L., Conley, Sabena M., Saadiq, Ishran M. , Obeidat, Yasin , Eirin, Alfonso , Zhu, Xiang-Yang, Wijnen, André J. van , Lerman, Lilach O. , Saadiq, Ishran M , Obeidat, Yasin , Pawar, Aditya S. , van Wijnen, Andre J , Eirin, Alfonso , Tang, Hui Ru , Lerman, Amir

Mayo Clinic

Epigenetics | September 6, 2020 | Volume: 16 | Issue: 7 | Pages: 705-717

10.1080/15592294.2020.1819663 | PMID 32893712 Get It

Locomotor muscle group III/IV afferents constrain stroke volume and contribute to exercise intolerance in human heart failure
Smith, Joshua R. , Joyner, Michael J. , Curry, Timothy B. , Borlaug, Barry A. , Keller‐Ross, Manda L. , Iterson, Erik H. Van , Olson, Thomas P. , Van Iterson, Erik H , Smith, Joshua R , Borlaug, Barry A , Joyner, Michael J , Keller-Ross, Manda

Mayo Clinic

The Journal of Physiology | September 4, 2020 | Volume: 598 | Issue: 23 | Pages: 5379-5390

10.1113/jp280333 | PMID 32886795 Get It

Key points Heart failure patients with reduced ejection fraction (HFrEF) exhibit severe limitations in exercise capacity ( peak). One of the primary peripheral mechanisms suggested to underlie exercise intolerance in HFrEF is excessive locomotor muscle group III/IV afferent feedback; however, this has never been investigated in human heart failure. HFrEF patients and controls performed an incremental exercise test to volitional exhaustion to determine peak with lumbar intrathecal fentanyl or placebo. During exercise, cardiac output, leg blood flow and radial artery and femoral venous blood gases were measured. With fentanyl, compared with placebo, patients with HFrEF achieved a higher peak workload, peak, cardiac output, stroke volume and leg blood flow. These findings suggest that locomotor muscle group III/IV afferent feedback in HFrEF leads to increased systemic vascular resistance, which constrains stroke volume, cardiac output and O2 delivery thereby impairing peak and thus exercise capacity. AbstractTo better understand the underlying mechanisms contributing to exercise limitation in heart failure with reduced ejection fraction (HFrEF), we investigated the influence of locomotor muscle group III/IV afferent inhibition via lumbar intrathecal fentanyl on peak exercise capacity ( peak) and the contributory mechanisms. Eleven HFrEF patients and eight healthy matched controls were recruited. The participants performed an incremental exercise test to volitional exhaustion to determine peak with lumbar intrathecal fentanyl or placebo. During exercise, cardiac output and leg blood flow () were measured via open‐circuit acetylene wash‐in technique and constant infusion thermodilution, respectively. Radial artery and femoral venous blood gases were measured. peak was 15% greater with fentanyl compared with placebo for HFrEF (P < 0.01), while no different in the controls. During peak exercise with fentanyl, cardiac output was 12% greater in HFrEF secondary to significant decreases in systemic vascular resistance and increases in stroke volume compared with placebo (all, P < 0.01). From placebo to fentanyl, leg , and O2 delivery were greater for HFrEF during peak exercise (all, P < 0.01), but not control. These findings indicate that locomotor muscle group III/IV afferent feedback in patients with HFrEF leads to increased systemic vascular resistance, which constrains stroke volume, cardiac output and O2 delivery, thereby impairing peak and thus exercise capacity. These findings have important clinical implications as peak is highly predictive of morbidity and mortality in HF.
Abstract CT011: Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL
Haddad, Tufia C. , Stringer-Reasor, Erica , Chien, A. Jo , Borges, Virginia, Nanda, Rita , Albain, Kathy S. , Müller, Aixa , Kemmer, Kathleen, Clark, Amy S. , Perlmutter, Jane , Melisko, Michelle , Schwab, Richard B. , Wilson, Amy , Singhrao, Ruby , Asare, Smita , Veer, Laura J. van’t , Sanil, Ashish, Berry, Donald A. , Pusztai, Lajos , Han, Hyo S , Yau, Christina , Wolf, Denise M. , Wallace, Anne M. , Shatsky, Rebecca , Helsten, Teresa L. , Boughey, Judy C. , Falkson, Carla I. , Mukhtar, Rita A. , Elias, Anthony , Yee, Douglas , Kalinsky, Kevin M. , Isaacs, Claudine , Thomas, Alexandra , Hylton, Nola M. , Symmans, W. Fraser , Rugo, Hope S. , DeMichele, Angela , Esserman, Laura J.

Mayo Clinic

Cancer Research | September 4, 2020 | Volume: 80 | Issue: 16_Supplement | Pages: CT011-CT011

10.1158/1538-7445.am2020-ct011 Get It

Abstract Background: I-SPY2 is a multicenter, phase 2 trial using response-adaptive randomization within molecular subtypes defined by receptor status and MammaPrint risk to evaluate novel agents as neoadjuvant therapy for breast cancer. The primary endpoint is pathologic complete response (pCR, ypT0/is ypN0)). DNA repair deficiency in cancer cells can lead to immunogenic neoantigens, activation of the STING pathway, and PARP inhibition can also upregulate PD-L1 expression. Based on these rationales we tested the combination of durvalumab (anti-PDL1), olaparib (PARP inhibitor) and paclitaxel in I-SPY2. Methods: Women with tumors ≥ 2.5 cm were eligible for screening. Only HER2 negative (HER2-) patients were eligible for this treatment, hormone receptor positive (HR+) patients had to have MammaPrint high molecular profile. Treatment included durvalumab 1500 mg every 4 weeks x 3, olaparib 100 mg twice daily through weeks 1-11 concurrent with paclitaxel 80 mg/m2 weekly x 12 (DOP) followed by doxorubicin/cyclophosphamide (AC) x 4. The control arm was weekly paclitaxel x 12 followed by AC x 4. All patients undergo serial MRI imaging and imaging response at 3 & 12 weeks combined with accumulating pCR data are used to estimate, and continuously update, predicted pCR rate for the trial arm. Regimens “graduation with success” when the Bayesian predictive probability of success in a 300-patient phase 3 neoadjuvant trial in the appropriate biomarker groups reaches &gt; 85%. Results: A total of 73 patients received DOP treatment including 21 HR- tumors (i.e. triple-negative breast cancer, TNBC) and 52 HR+ tumors between May 2018 - June 2019. The control group included 299 patients with HER2- tumors. The DOP arm graduated in June 2019, 13 months after enrollment had started, for all HER2- negative and the HR+/HER2- cohorts with &gt; 0.85% predictive probabilities of success. 72 patient completed surgery and evaluable for pCR, the final predicted probabilities of success in a future phase III trial to demonstrate higher pCR rate with DOP compared to control are 81% for all HER2- cancers (estimated pCR rate 37%), 80% for TNBC (estimated pCR rate 47%) and 74.5% for HR+/HER2- patients (estimated pCR rate 28%). Association between pCR and germline BRCA status and immune gene expression including PDL1 will be presented at the meeting. No unexpected toxicities were seen, but 10 patients (14%) had possibly immune or olaparib related grade 2/3 AEs (3 pneumonitis, 2 adrenal insufficiency, 1 colitis, 1 pancreatitis, 2 elevated LFT, 1 skin toxicity, 2 hypothyroidism, 1 hyperthyroidism, 1 esophagitis). Conclusion: I-SPY2 demonstrated a significant improvement in pCR with durvalumab and olaparib included with paclitaxel compared to chemotherapy alone in women with stage II/III high-risk, HER2-negative breast cancer, improvement was seen in both the HR+ and TNBC subsets. Citation Format: Lajos Pusztai, Hyo S. Han, Christina Yau, Denise Wolf, Anne M. Wallace, Rebecca Shatsky, Teresa Helsten, Judy C. Boughey, Tufia Haddad, Erica Stringer-Reasor, Carla Falkson, A. Jo Chien, Rita Mukhtar, Anthony Elias, Borges Virginia, Rita Nanda, Douglas Yee, Kevin Kalinsky, Kathy S. Albain, Aixa Soyano Muller, Kathleen Kemmer, Amy S. Clark, Claudine Isaacs, Alexandra Thomas, Nola Hylton, W. Fraser Symmans, Jane Perlmutter, Michelle Melisko, Hope S. Rugo, Richard Schwab, Amy Wilson, Amy Wilson, Ruby Singhrao, Smita Asare, Laura J. van't Veer, Angela M. DeMichele, Ashish Sanil, Donald A. Berry, Laura J. Esserman, Trial Consortium I-SPY 2. Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr CT011.